Meda: Retigabine Applications Filed In US, Europe
DOW JONES NEWSWIRES
STOCKHOLM -(Dow Jones)- Swedish pharmaceutical company Meda said Monday its
partner Valeant Pharmaceuticals has completed the New Drug Application and
Marketing Authorisation Application for epilepsy treatment Retigabine on Oct.
30.
MAIN FACTS:
-Meda is entitled to receive significant royalties and certain milestone
payments on the Retigabine substance.
-GlaxoSmithKline has signed a worldwide collaboration agreement with Valeant
Pharmaceuticals for Retigabine.
-By Stockholm Bureau, Dow Jones Newswires; +46-8-5451-3090; djnews.stockholm@
dowjones.com
(END) Dow Jones Newswires
11-02-090836ET
Copyright (c) 2009 Dow Jones & Company, Inc.
|